Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Study or Subgroup	Sacubitril/valsartan Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
11.3.1 Valsartan						
PARAGON-HF 2019	342	2407	349	2389	96.9%	0.97 [0.85, 1.12]
PARAMOUNT 2012	1	149	2	152	0.5%	0.51 [0.05, 5.57]
Subtotal (95% CI)		**2556**		**2541**	**97.5%**	**0.97 [0.85, 1.11]**
Total events	343		351			
Heterogeneity: Chi² = 0.28, df = 1 (P = 0.60); I² = 0%						
Test for overall effect: Z = 0.43 (P = 0.66)						
11.3.3 Usual care						
Huang SB 2019	2	39	9	38	2.5%	0.22 [0.05, 0.94]
Subtotal (95% CI)		**39**		**38**	**2.5%**	**0.22 [0.05, 0.94]**
Total events	2		9			
Heterogeneity: Not applicable						
Test for overall effect: Z = 2.05 (P = 0.04)						
Total (95% CI)		**2595**		**2579**	**100.0%**	**0.95 [0.83, 1.09]**
Total events	345		360			
Heterogeneity: Chi² = 4.28, df = 2 (P = 0.12); I² = 53%						
Test for overall effect: Z = 0.72 (P = 0.47)						
Test for subgroup differences: Chi² = 3.99, df = 1 (P = 0.05), I² = 74.9%						

Risk Ratio
M-H, Fixed, 95% CI

0.05 0.2 1 5 20
Sacubitril/valsartan   Control